Browse INHBE

Summary
SymbolINHBE
Nameinhibin, beta E
Aliases activin; MGC4638; activin beta E; activin beta-E chain; Inhibin beta E chain
Chromosomal Location12q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted
Domain PF00019 Transforming growth factor beta like domain
Function

Inhibins and activins inhibit and activate, respectively, the secretion of follitropin by the pituitary gland. Inhibins/activins are involved in regulating a number of diverse functions such as hypothalamic and pituitary hormone secretion, gonadal hormone secretion, germ cell development and maturation, erythroid differentiation, insulin secretion, nerve cell survival, embryonic axial development or bone growth, depending on their subunit composition. Inhibins appear to oppose the functions of activins.

> Gene Ontology
 
Biological Process GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0010862 positive regulation of pathway-restricted SMAD protein phosphorylation
GO:0060389 pathway-restricted SMAD protein phosphorylation
GO:0060393 regulation of pathway-restricted SMAD protein phosphorylation
GO:0060395 SMAD protein signal transduction
GO:0090092 regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090100 positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
Molecular Function GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0005160 transforming growth factor beta receptor binding
GO:0005179 hormone activity
GO:0008083 growth factor activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04350 TGF-beta signaling pathway
hsa04550 Signaling pathways regulating pluripotency of stem cells
Reactome R-HSA-209822: Glycoprotein hormones
R-HSA-392499: Metabolism of proteins
R-HSA-209952: Peptide hormone biosynthesis
R-HSA-2980736: Peptide hormone metabolism
Summary
SymbolINHBE
Nameinhibin, beta E
Aliases activin; MGC4638; activin beta E; activin beta-E chain; Inhibin beta E chain
Chromosomal Location12q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between INHBE and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between INHBE and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27364554Melanoma; Lung carcinomaPromote immunityIn vivo, activin A-stimulated DCs demonstrate a significantly increased ability to induce tumor-specific CTLs and inhibit the growth of melanoma and lung carcinoma, which relies on DC-derived BAFF and APRIL, as knockdown of the BAFF and APRIL gene expression in activin A-treated DCs blocks augmentation of their antitumor potential.
Summary
SymbolINHBE
Nameinhibin, beta E
Aliases activin; MGC4638; activin beta E; activin beta-E chain; Inhibin beta E chain
Chromosomal Location12q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of INHBE in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolINHBE
Nameinhibin, beta E
Aliases activin; MGC4638; activin beta E; activin beta-E chain; Inhibin beta E chain
Chromosomal Location12q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of INHBE in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1720.692
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1640.817
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.4280.5
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.560.323
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4840.616
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.6450.54
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.5770.334
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.9550.359
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1020.924
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0890.932
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.1920.897
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.160.533
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of INHBE in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolINHBE
Nameinhibin, beta E
Aliases activin; MGC4638; activin beta E; activin beta-E chain; Inhibin beta E chain
Chromosomal Location12q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of INHBE. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolINHBE
Nameinhibin, beta E
Aliases activin; MGC4638; activin beta E; activin beta-E chain; Inhibin beta E chain
Chromosomal Location12q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of INHBE. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by INHBE.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolINHBE
Nameinhibin, beta E
Aliases activin; MGC4638; activin beta E; activin beta-E chain; Inhibin beta E chain
Chromosomal Location12q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of INHBE. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolINHBE
Nameinhibin, beta E
Aliases activin; MGC4638; activin beta E; activin beta-E chain; Inhibin beta E chain
Chromosomal Location12q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of INHBE expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolINHBE
Nameinhibin, beta E
Aliases activin; MGC4638; activin beta E; activin beta-E chain; Inhibin beta E chain
Chromosomal Location12q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between INHBE and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolINHBE
Nameinhibin, beta E
Aliases activin; MGC4638; activin beta E; activin beta-E chain; Inhibin beta E chain
Chromosomal Location12q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting INHBE collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.